AAP
PROK icon

Arax Advisory Partners’s ProKidney PROK Stock Holding History

Arax Advisory Partners’s Portfolio PROK Stock Details PROK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$116 Sell
61
-4
-6% -$8 ﹤0.01% 3600
2025
Q4 		$146 Sell
65
-183
-74% -$481 ﹤0.01% 3768
2025
Q3 		$600 Buy
+248
New +$660 ﹤0.01% 3345

Other funds holding PROK

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
AGP
Artia Global Partners Miami, Florida $499M AUM 186.05% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Arax Advisory Partners's PROK Position: Q1 2026 in Review

Arax Advisory Partners reduced its ProKidney (PROK) stake by 6.2% in Q1 2026, selling an estimated $8 and leaving 61 shares worth $116. The position accounts for ﹤0.01% of the portfolio, ranked #3600.

Arax Advisory Partners first reported a position in PROK in Q3 2025 and has held it in 3 quarters since. The position peaked at $600 in Q3 2025. 71 funds tracked by Wall St. Rank hold PROK as of Q1 2026.

  • Arax Advisory Partners held 61 shares of ProKidney worth $116 as of Q1 2026.
  • Arax Advisory Partners sold 4 ProKidney shares in Q1 2026, an estimated $8.
  • ProKidney made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3600 holding.
  • Arax Advisory Partners first reported a position in ProKidney in Q3 2025 and has held it in 3 quarters since.
  • Arax Advisory Partners's ProKidney position peaked at $600 in Q3 2025.
  • 71 funds tracked by Wall St. Rank held ProKidney as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.